{"id":"fludarabine-flud","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"30-50","effect":"Infection"},{"rate":"20-40","effect":"Nausea and vomiting"},{"rate":"20-30","effect":"Fever"},{"rate":"20-30","effect":"Fatigue"},{"rate":"10-20","effect":"Neurotoxicity"},{"rate":"5-10","effect":"Tumor lysis syndrome"}]},"_chembl":{"chemblId":"CHEMBL1096882","moleculeType":"Small molecule","molecularWeight":"365.21"},"_dailymed":{"setId":"cf5255cc-91fd-4132-973b-764dba142eae","title":"FLUDARABINE (FLUDARABINE PHOSPHATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fludarabine is a fluorinated purine nucleoside analog that is phosphorylated intracellularly to its active form, fludarabine triphosphate. This active metabolite inhibits ribonucleotide reductase and DNA polymerase, preventing DNA synthesis and repair. It is particularly effective against lymphoid malignancies because lymphocytes have high levels of deoxycytidine kinase, the enzyme responsible for its activation.","oneSentence":"Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to disruption of DNA synthesis and cell death in rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:54:53.263Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Follicular lymphoma"},{"name":"Small lymphocytic lymphoma (SLL)"}]},"trialDetails":[{"nctId":"NCT07025824","phase":"PHASE2","title":"Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2025-09","conditions":"AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome)","enrollment":220},{"nctId":"NCT01540812","phase":"","title":"Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2012-02","conditions":"Acute Lymphoblastic Leukemia","enrollment":418}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fludarabine (Flud)","genericName":"Fludarabine (Flud)","companyName":"Technische Universität Dresden","companyId":"technische-universit-t-dresden","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to disruption of DNA synthesis and cell death in rapidly dividing cells. Used for Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Small lymphocytic lymphoma (SLL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}